Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc (NASDAQ: INMB) is a clinical-stage biotechnology pipeline targeting cancer and neurodegenerative diseases through innovative immunotherapies. This page provides investors and researchers with centralized access to official announcements, trial updates, and strategic developments.
Discover the latest progress across INMB’s two core platforms: the DN-TNF therapies addressing chronic inflammation and the NK cell priming technology combatting resistant tumors. Our news collection includes earnings reports, clinical trial milestones, partnership announcements, and regulatory filings.
All content is sourced directly from company disclosures to ensure accuracy. Bookmark this page for efficient tracking of INMB’s advancements in precision immunotherapies, including updates on INKmune™ and XPro™ clinical programs. Visit regularly to stay informed about developments in innate immune system modulation.
INmune Bio Inc. announced its first-quarter 2024 financial results and provided a business update, highlighting milestones in their DN-TNF, INB03 cancer, and INKmune platforms. The company raised $14.5 million in equity capital, completed the first dosing in a Phase I/II trial of INKmune for mCRPC, and disclosed a net loss of $11.0 million for the quarter ended March 31, 2024.
INmune Bio Inc. will report its first quarter 2024 financial results and provide a corporate update on May 9. The clinical-stage immunology company is focused on developing treatments leveraging a patient's innate immune system to combat diseases. A conference call and webcast will be hosted at 4:30 PM ET on the same day.
INmune Bio Inc. provides an update on two patients from the Phase 1b Alzheimer’s Disease Trial who have been receiving XPro™ for over three years under the Australian compassionate use program. Both patients have shown stable cognitive function and a desire to continue treatment. The long-term administration of XPro™ has been safe and well-tolerated, according to primary care physicians.
INmune Bio Inc., a clinical-stage immunology company, has completed the first cohort and initiated the second cohort of a Phase 1/2 study of INKmune™ Natural Killer Cell Therapy for metastatic castration-resistant prostate cancer. The company is encouraged by the safety and efficacy of the therapy, with approval granted to proceed with the second dose level. Prof. Mark Lowdell Ph.D., CSO of INmune Bio, highlights the potential of INKmune to transform resting NK cells into cancer-killing cells, offering a promising therapy for prostate cancer patients.
FAQ
What is the current stock price of Inmune Bio (INMB)?
What is the market cap of Inmune Bio (INMB)?
